FACE-OFF: Low-Risk MDS ASH 2025
EP. 1: Introduction and Phase 3 COMMANDS Trial
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD FACE-OFF: Low-Risk MDS ASH 2025
EP. 2: Clinical Implications of COMMANDS Trial
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD FACE-OFF: Low-Risk MDS ASH 2025
EP. 3: RWO 1L lupatercept vs 2L ESA
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Encountering an error while trying to access content? Discover solutions to troubleshoot and resolve connectivity issues effectively.
EP. 4: Insights into RWO 1L lupatercept vs 2L ESA
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.
EP. 5: RWO Hb Assessment in 1L
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Explore real-world outcomes of hemoglobin treatment in low-risk MDS patients, comparing luspatercept and ESA therapies in a recent study.
EP. 6: IMERGE Trial – ASH 2025 Updates
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Explore the promising long-term outcomes of the IMERG trial, highlighting Emtresat's efficacy and safety for lower-risk MDS patients.
EP. 7: Debate Topic 1: Treatment initiation
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Experts debate the optimal timing for initiating treatment in low-risk MDS, emphasizing early intervention to enhance patient quality of life.
EP. 8: Debate Topic 2: Defining 1L therapy
BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD Experts debate the efficacy of luspatercept versus erythropoietin in treating low-risk MDS, emphasizing individualized patient care and emerging therapies.
